Sarcoidosis Induced by Adalimumab in Rheumatoid Arthritis

Lee, Seung Ho; Kim, Sa Il; Song, June Seok; Kim, Tae Hyung; Kim, Sang Heon; Yoon, Ho Joo; Kim, So Yeon; Shin, Dong Ho; Kwak, Hyun Jung

doi:10.4046/trd.2011.71.6.464

Cited by 2 publications

(3 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The development of cutaneous sarcoidosis as a paradoxical adverse event of TNF-α blockers has been reported in the literature ( Table 1 ) 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 . The exact pathophysiology of the paradoxical event remains unknown; however, it is assumed that the administration of anti-TNF agents to control inflammatory disorders can disturb TNF-α level in the signaling pathway and results in unintended adverse effects 9 .…”

Section: Discussionmentioning

confidence: 99%

“…Paradoxically, psoriasis and cutaneous sarcoidosis have been reported as adverse effects of anti-TNF therapy 1 2 . New onset of systemic sarcoidosis during treatment with TNF-α blockers is well known, but cutaneous sarcoidosis caused by this agent has been rarely reported in children in the dermatologic literature 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 . Herein, we report the first case of an erythrodermic form of cutaneous sarcoidosis during anti-TNF-α in juvenile rheumatoid arthritis (JRA) and review TNF-α blocker-induced cutaneous sarcoidosis in previous studies.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Tumor Necrosis Factor Alpha Blocker-Induced Erythrodermic Sarcoidosis in with Juvenile Rheumatoid Arthritis: A Case Report and Review of the Literature

et al. 2017

View full text Add to dashboard Cite

The development of cutaneous sarcoidosis as a paradoxical adverse event of tumor necrosis factor alpha (TNF-α) blockers has been reported in the literature; however, an erythrodermic form of cutaneous sarcoidosis during anti-TNF-α therapy has not yet been reported. Herein, we report the first case of an erythrodermic form of cutaneous sarcoidosis during anti-TNF-α therapy and review previous studies of cutaneous sarcoidosis. A 6-year-old Korean girl who had been suffering from juvenile rheumatoid arthritis presented with generalized erythematous skin eruption involving more than about 90% of her body surface area. After 14 months of etanercept treatment, the new erythematous skin eruption had developed and progressed into generalized erythroderma. Exclusion of suspected co-medication had been performed based on medication history. She had no other systemic symptoms, and ophthalmologic and neurologic examinations were normal. Histopathologic findings of the skin lesion revealed diffuse non-caseating granulomatous infiltrates composed of epithelioid histiocytes with sparse lymphocytes involving the entire dermis. Periodic-acid-Schiff and acid-fast stains were negative, and acid-fast bacilli was not detected by polymerase chain reaction of the skin biopsy. Based on clinicopathologic findings, she was diagnosed with etanercept-induced sarcoidal granuloma. After discontinuation of the suspected agent, the lesions spontaneously disappeared.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Tumor Necrosis Factor Alpha Blocker-Induced Erythrodermic Sarcoidosis in with Juvenile Rheumatoid Arthritis: A Case Report and Review of the Literature

et al. 2017

View full text Add to dashboard Cite

show abstract

“…In Korea, two cases of sarcoidosis were earlier reported: adalimumab-induced disease in a patient with rheumatoid arthritis [7] and etanercept-induced sarcoidosis in a patient with AS [8]. A literature search identified 45 cases of sarcoidosis (including Korean cases) [5,[7][8][9][10] that developed during anti-TNF therapy. The mean patient age was 47.53 years, and the male-to-female ratio was 2:3.…”

Section: Discussionmentioning

confidence: 99%

A Case of Sarcoidosis That Improved upon Discontinuation of Etanercept

Kang

Ahn

et al. 2016

J Rheum Dis

View full text Add to dashboard Cite

A 31-year-old man who had been prescribed etanercept over a 3-year period for treatment of ankylosing spondylitis presented with newly developed dry cough, chills, myalgia, and weight loss. Chest computed tomography showed multiple reticulonodular pulmonary infiltrates and bilateral mediastinal, hilar, and peribronchial lymphadenopathy. Biopsy of a paratracheal lymph node revealed chronic granulomatous inflammation without necrosis, and the serum angiotensin-converting enzyme level was elevated. Sarcoidosis was diagnosed. His laboratory and radiological findings, and clinical symptoms improved only after discontinuation of etanercept without treatment. Although etanercept-induced sarcoidosis is rare, this case report suggests that sarcoidosis should be considered in the differential diagnosis of patients treated with the tumor necrosis factor inhibitor. (J Rheum Dis 2016;23:187-192)

show abstract

Sarcoidosis Induced by Adalimumab in Rheumatoid Arthritis

Cited by 2 publications

References 14 publications

Tumor Necrosis Factor Alpha Blocker-Induced Erythrodermic Sarcoidosis in with Juvenile Rheumatoid Arthritis: A Case Report and Review of the Literature

Tumor Necrosis Factor Alpha Blocker-Induced Erythrodermic Sarcoidosis in with Juvenile Rheumatoid Arthritis: A Case Report and Review of the Literature

A Case of Sarcoidosis That Improved upon Discontinuation of Etanercept

Contact Info

Product

Resources

About